Relmada Therapeutics (RLMD) Projected to Release Quarterly Earnings on Thursday

Relmada Therapeutics (NASDAQ:RLMD) is anticipated to release its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect the company to post earnings of ($0.1450) per share for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:30 PM ET.

Relmada Therapeutics (NASDAQ:RLMD) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.09. On average, analysts expect Relmada Therapeutics to post ($0.62) EPS for the current fiscal year and ($0.78) EPS for the next fiscal year.

Relmada Therapeutics Stock Down 2.3%

Shares of Relmada Therapeutics stock opened at $4.17 on Thursday. Relmada Therapeutics has a 12 month low of $2.42 and a 12 month high of $8.00. The business has a fifty day simple moving average of $3.81 and a 200 day simple moving average of $5.32. The stock has a market cap of $444.81 million, a PE ratio of -4.63 and a beta of 0.62.

Insider Buying and Selling

In other Relmada Therapeutics news, CFO Maged Shenouda acquired 79,800 shares of the company’s stock in a transaction that occurred on Thursday, September 10th. The shares were acquired at an average price of $4.25 per share, with a total value of $339,150.00. Following the purchase, the chief financial officer owned 1,000,000 shares of the company’s stock, valued at $4,250,000. This represents a 8.67% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 14.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Relmada Therapeutics in a research note on Monday, September 14th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $12.00.

About Relmada Therapeutics

Relmada Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for central nervous system disorders. The company’s research has primarily targeted conditions with significant unmet medical needs, including major depressive disorder and other neuropsychiatric diseases.

Relmada’s lead investigational product is REL-1017, also known as esmethadone or dextromethadone. The orally administered compound is designed to modulate the N-methyl-D-aspartate (NMDA) receptor and has been studied as a potential adjunctive treatment for major depressive disorder in patients who do not respond adequately to standard antidepressants.